Literature DB >> 25034005

Pericytes in chronic lung disease.

Jessica E Rowley1, Jill R Johnson.   

Abstract

Pericytes are mesenchymal cells embedded within the abluminal surface of the endothelium of microvessels such as capillaries, pre-capillary arterioles, post-capillary and collecting venules, where they maintain microvascular homeostasis and participate in angiogenesis. In addition to their roles in supporting the vasculature and facilitating leukocyte extravasation, pericytes have been recently investigated as a subpopulation of mesenchymal stem cells (MSCs) due to their capacity to differentiate into numerous cell types including the classic MSC triad, i.e. osteocytes, chondrocytes and adipocytes. Other studies in models of fibrotic inflammatory disease of the lung have demonstrated a vital role of pericytes in myofibroblast activation, collagen deposition and microvascular remodelling, which are hallmark features of chronic lung diseases such as asthma, chronic obstructive pulmonary disorder, pulmonary fibrosis and pulmonary hypertension. Further studies into the mechanisms of the pericyte-to-myofibroblast transition and migration to fibrotic foci will hopefully clarify the role of these cells in chronic lung disease and confirm the importance of pericytes in human fibrotic pulmonary disease.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2014        PMID: 25034005     DOI: 10.1159/000365051

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  13 in total

1.  Nestin-expressing vascular wall cells drive development of pulmonary hypertension.

Authors:  Farhan Saboor; Ansgar N Reckmann; Claudia U M Tomczyk; Dorothea M Peters; Norbert Weissmann; Andre Kaschtanow; Ralph T Schermuly; Tatyana V Michurina; Grigori Enikolopov; Dieter Müller; Andrea Mietens; Ralf Middendorff
Journal:  Eur Respir J       Date:  2015-12-23       Impact factor: 16.671

2.  Single-cell analysis reveals fibroblast heterogeneity and myofibroblasts in systemic sclerosis-associated interstitial lung disease.

Authors:  Eleanor Valenzi; Melissa Bulik; Tracy Tabib; Christina Morse; John Sembrat; Humberto Trejo Bittar; Mauricio Rojas; Robert Lafyatis
Journal:  Ann Rheum Dis       Date:  2019-08-12       Impact factor: 19.103

3.  Pericyte MyD88 and IRAK4 control inflammatory and fibrotic responses to tissue injury.

Authors:  Irina A Leaf; Shunsaku Nakagawa; Bryce G Johnson; Jin Joo Cha; Kristen Mittelsteadt; Kevin M Guckian; Ivan G Gomez; William A Altemeier; Jeremy S Duffield
Journal:  J Clin Invest       Date:  2016-11-21       Impact factor: 14.808

Review 4.  Lung Pericytes and Resident Fibroblasts: Busy Multitaskers.

Authors:  Luke Barron; Sina A Gharib; Jeremy S Duffield
Journal:  Am J Pathol       Date:  2016-08-21       Impact factor: 4.307

5.  Chemokine CXCL12 drives pericyte accumulation and airway remodeling in allergic airway disease.

Authors:  Rebecca Bignold; Bushra Shammout; Jessica E Rowley; Mariaelena Repici; John Simms; Jill R Johnson
Journal:  Respir Res       Date:  2022-07-13

6.  IL-1β and Inflammasome Activity Link Inflammation to Abnormal Fetal Airway Development.

Authors:  Ashley N Stouch; Alyssa M McCoy; Rachel M Greer; Omar Lakhdari; Fiona E Yull; Timothy S Blackwell; Hal M Hoffman; Lawrence S Prince
Journal:  J Immunol       Date:  2016-03-07       Impact factor: 5.422

7.  Human pericytes adopt myofibroblast properties in the microenvironment of the IPF lung.

Authors:  Parid Sava; Anand Ramanathan; Amelia Dobronyi; Xueyan Peng; Huanxing Sun; Adrian Ledesma-Mendoza; Erica L Herzog; Anjelica L Gonzalez
Journal:  JCI Insight       Date:  2017-12-21

8.  ROS-induced endothelial stress contributes to pulmonary fibrosis through pericytes and Wnt signaling.

Authors:  Annika Andersson-Sjöland; Jenny C Karlsson; Kristina Rydell-Törmänen
Journal:  Lab Invest       Date:  2015-09-14       Impact factor: 5.662

9.  Characterization of human PDGFR-β-positive pericytes from IPF and non-IPF lungs.

Authors:  Carole L Wilson; Sarah E Stephenson; Jean Paul Higuero; Carol Feghali-Bostwick; Chi F Hung; Lynn M Schnapp
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-10-18       Impact factor: 5.464

Review 10.  Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.

Authors:  Lutz Wollin; Eva Wex; Alexander Pautsch; Gisela Schnapp; Katrin E Hostettler; Susanne Stowasser; Martin Kolb
Journal:  Eur Respir J       Date:  2015-03-05       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.